Advanced Therapies: Invention or Innovation?
By Liam Tremble
September 23, 2026
Scientific breakthroughs are only true innovations if healthcare systems can deliver them safely, manage their toxicities, and make them accessible at scale
6 min read
False
Advertisement
Cell & Gene
“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting
September 23, 2026
Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors
2 min read
Musings from The Power List: Michael May
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
Long-Term Data Boost MCO-010
September 21, 2026
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
2 min read
Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?
September 18, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale
1 min read
Novartis and BMS Pause Autoimmune CAR T Trials Over Safety Concerns
September 16, 2026
Three deaths linked to immune effector cell-associated hemophagocytic syndrome prompt Novartis to halt eight rap-cel studies
2 min read
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
September 16, 2026
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
2 min read
AI-Designed Binder Improves CAR T Cell Activity in Mice
September 15, 2026
Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control
2 min read
Biomarker Could Predict Response to Low-Dose CAR T Cell Therapy
September 14, 2026
CD27-negative, CD39-negative CAR T cells were associated with treatment response when limited cell numbers were administered
3 min read
Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?
September 11, 2026
IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients
1 min read
